Get started
Petros Pharmaceuticals, Inc.Petros Pharmaceuticals, Inc.Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PTPI chart


Full chart

PTPI upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.26 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−8.16 M‬ USD
Revenue (FY)
‪5.82 M‬ USD
Shares float
‪9.08 M‬
Beta (1Y)
0.92

Employees


Employees (FY)
21
Change (1Y)
−3 −12.50%
Revenue / Employee (1Y)
‪277.26 K‬ USD
Net income / Employee (1Y)
‪−388.72 K‬ USD

About Petros Pharmaceuticals, Inc.


Sector
Health Technology
CEO
John Shulman
Headquarters
New York
Website
petrospharma.com
FIGI
BBG00TYL0TW3
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

PTPI news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PTPI is 0.3170 USD — it has decreased by −4.88% in the past 24 hours. Watch Petros Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Petros Pharmaceuticals, Inc. stocks are traded under the ticker PTPI.
PTPI stock has fallen by −22.31% compared to the previous week, the month change is a −8.80% fall, over the last year Petros Pharmaceuticals, Inc. has showed a −76.34% decrease.
We've gathered analysts' opinions on Petros Pharmaceuticals, Inc. future price: according to them, PTPI price has a max estimate of 1.00 USD and a min estimate of 1.00 USD. Watch PTPI chart and read a more detailed Petros Pharmaceuticals, Inc. stock forecast: see what analysts think of Petros Pharmaceuticals, Inc. and suggest that you do with its stocks.
PTPI reached its all-time high on Dec 18, 2020 with the price of 59.5990 USD, and its all-time low was 0.2821 USD and was reached on Aug 21, 2024. View more price dynamics on PTPI chart.
See other stocks reaching their highest and lowest prices.
PTPI stock is 6.50% volatile and has beta coefficient of 0.92. Track Petros Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Petros Pharmaceuticals, Inc. there?
Today Petros Pharmaceuticals, Inc. has the market capitalization of ‪3.26 M‬, it has decreased by −9.25% over the last week.
Yes, you can track Petros Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Petros Pharmaceuticals, Inc. is going to release the next earnings report on Nov 27, 2024. Keep track of upcoming events with our Earnings Calendar.
Petros Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪1.42 M‬ USD, despite the estimated figure of ‪1.42 M‬ USD. In the next quarter, revenue is expected to reach ‪1.34 M‬ USD.
PTPI net income for the last quarter is ‪−662.03 K‬ USD, while the quarter before that showed ‪−2.16 M‬ USD of net income which accounts for 69.39% change. Track more Petros Pharmaceuticals, Inc. financial stats to get the full picture.
No, PTPI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 21.00 employees. See our rating of the largest employees — is Petros Pharmaceuticals, Inc. on this list?
Like other stocks, PTPI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Petros Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Petros Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Petros Pharmaceuticals, Inc. stock shows the sell signal. See more of Petros Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.